Prognosis can be affected by the type of genetic mutation that the person with<unk>  has. Some examples of genetic mutations and their prognoses are: mutations in the IGHV region are associated with a median overall survival (OS) of more than 20–25 years, while no mutations in this region is associated with a median OS of 8–10 years; deletion of chromosome 13q is associated with a median OS of 17 years; and trisomy of chromosome 12, as well as deletion of chromosome 11q, is associated with a median OS of 9–11 years. While prognosis is highly variable and dependent on various factors including these mutations, the average 5-year relative survival is 86.1%. Telomere length has been suggested to be a valuable prognostic indicator of survival. In addition, a person's sex has been found to have an impact on<unk>  prognosis and treatment efficacy. More specifically, females have been found to survive longer (without disease progression) than males, when treated with certain medications.
Chronic lymphocytic leukemia
Hairy cell leukemia
Chronic neutrophilic leukemia
Infectious mononucleosis
AIDS-related lymphoma
Acute lymphoblastic leukemia
Prolymphocytic leukemia
Persistent polyclonal B-cell lymphocytosis